| scholarly article | Q13442814 |
| P2093 | author name string | Williams RD | |
| Davidson BL | |||
| Anderson RD | |||
| Ratliff TL | |||
| Griffith TS | |||
| P2860 | cites work | Lethal effect of the anti-Fas antibody in mice | Q36696599 |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | apoptotic process | Q14599311 |
| TNF | Q18032037 | ||
| Adenoviridae | Q193447 | ||
| P304 | page(s) | 2886-2894 | |
| P577 | publication date | 2000-09-01 | |
| P1433 | published in | Journal of Immunology | Q3521441 |
| P1476 | title | Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis | |
| P478 | volume | 165 |
| Q39744489 | A novel molecule integrating therapeutic and diagnostic activities reveals multiple aspects of stem cell-based therapy. |
| Q40565608 | A tumor-targeted and conditionally replicating oncolytic adenovirus vector expressing TRAIL for treatment of liver metastases. |
| Q40582634 | AAV-encoded expression of TRAIL in experimental human colorectal cancer leads to tumor regression. |
| Q40440255 | Absence of caspase 3 activation in neoplastic cells of nasopharyngeal carcinoma biopsies predicts rapid fatal outcome. |
| Q41275175 | Activation of systemic antitumor immunity via TRAIL-induced apoptosis |
| Q40075397 | Active FKHRL1 overcomes imatinib resistance in chronic myelogenous leukemia-derived cell lines via the production of tumor necrosis factor-related apoptosis-inducing ligand |
| Q34244279 | Adeno-associated virus-mediated doxycycline-regulatable TRAIL expression suppresses growth of human breast carcinoma in nude mice |
| Q40605148 | Adenoviral (full-length) Apo2L/TRAIL gene transfer is an ineffective treatment strategy for malignant glioma |
| Q63865750 | Adenovirus-TRAIL can overcome TRAIL resistance and induce a bystander effect |
| Q40488102 | Adenovirus-mediated FLT1-targeted proapoptotic gene therapy of human prostate cancer |
| Q40391803 | Adenovirus-mediated IKKbetaKA expression sensitizes prostate carcinoma cells to TRAIL-induced apoptosis |
| Q34384021 | Advances in Viral Vector-Based TRAIL Gene Therapy for Cancer |
| Q36474111 | Anti-liver cancer activity of TNF-related apoptosis-inducing ligand gene and its bystander effects |
| Q37140126 | Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy |
| Q43674000 | Bcl-2 over-expression and activation of protein kinase C suppress the trail-induced apoptosis in Jurkat T cells |
| Q40367155 | Cancer gene therapy using a novel secretable trimeric TRAIL. |
| Q28360690 | Cancer gene therapy using a survivin mutant adenovirus |
| Q40734169 | Caspase-8 activation is necessary but not sufficient for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in the prostatic carcinoma cell line LNCaP. |
| Q38869957 | Clinically applicable human adipose tissue-derived mesenchymal stem cells delivering therapeutic genes to brainstem gliomas |
| Q40589856 | Cloning and analysis of human UroplakinII promoter and its application for gene therapy in bladder cancer |
| Q40639389 | Combination of TRAIL gene therapy and chemotherapy enhances antitumor and antimetastasis effects in chemosensitive and chemoresistant breast cancers. |
| Q40075494 | Combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and canstatin gene suppression therapy on breast tumor xenograft growth in mice |
| Q50066591 | Combination of vorinostat and adenovirus-TRAIL exhibits a synergistic antitumor effect by increasing transduction and transcription of TRAIL in lung cancer cells. |
| Q45855281 | Combined TRAIL and Bax gene therapy prolonged survival in mice with ovarian cancer xenograft |
| Q40081513 | DcR2 (TRAIL-R4) siRNA and adenovirus delivery of TRAIL (Ad5hTRAIL) break down in vitro tumorigenic potential of prostate carcinoma cells |
| Q35613236 | Death receptor-induced cell death in prostate cancer |
| Q46383982 | Depsipeptide (FR901228) enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid rafts |
| Q28386614 | Diet-induced obesity alters dendritic cell function in the presence and absence of tumor growth |
| Q33758166 | Effective TRAIL-based immunotherapy requires both plasmacytoid and CD8α dendritic cells |
| Q35006015 | Efficacy of adenovirally expressed soluble TRAIL in human glioma organotypic slice culture and glioma xenografts |
| Q39639739 | Efficient Melanoma Cell Killing and Reduced Melanoma Growth in Mice by a Selective Replicating Adenovirus Armed with Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand |
| Q39360115 | Enhanced effects of TRAIL-endostatin-based double-gene-radiotherapy on suppressing growth, promoting apoptosis and inducing cell cycle arrest in vascular endothelial cells |
| Q40321046 | Enhancement of Ad5-TRAIL cytotoxicity against renal cell carcinoma with histone deacetylase inhibitors |
| Q35624010 | Enhancing the therapeutic efficacy of adenovirus in combination with biomaterials. |
| Q34474267 | Evaluating the effect of therapeutic stem cells on TRAIL resistant and sensitive medulloblastomas |
| Q53653814 | Ex vivo purging of leukemia cells using tumor-necrosis-factor-related apoptosis-inducing ligand in hematopoietic stem cell transplantation. |
| Q35887319 | Exploiting natural anti-tumor immunity for metastatic renal cell carcinoma. |
| Q40431186 | Fiber-modified adenoviral vector expressing the tumor necrosis factor-related apoptosis-inducing ligand gene from the human telomerase reverse transcriptase promoter induces apoptosis in human hepatocellular carcinoma cells |
| Q36349678 | Gene delivery and gene therapy of prostate cancer |
| Q35127888 | Gene expression profiling associated with angiotensin II type 2 receptor-induced apoptosis in human prostate cancer cells |
| Q35609061 | Gene therapy for carcinoma of the breast |
| Q40189071 | Histone deacetylase inhibitors enhance Ad5-TRAIL killing of TRAIL-resistant prostate tumor cells through increased caspase-2 activity |
| Q38334935 | IFN-gamma enhances TRAIL-induced apoptosis through IRF-1. |
| Q84461412 | Importance of TNF-related apoptosis-inducing ligand in pathogenesis of interstitial cystitis |
| Q36424294 | In vitro and in vivo growth inhibition of drug-resistant ovarian carcinoma cells using a combination of cisplatin and a TRAIL-encoding retrovirus |
| Q55471304 | In vivo imaging of S-TRAIL-mediated tumor regression and apoptosis. |
| Q64378714 | Inhibition of human lung cancer growth following adenovirus-mediated mda-7 gene expression in vivo |
| Q40521747 | Inhibition of the NF-kappaB pathway enhances TRAIL-mediated apoptosis in neuroblastoma cells |
| Q34042354 | Intratumoral versus intravenous gene therapy using a transcriptionally targeted viral vector in an orthotopic hepatocellular carcinoma rat model. |
| Q39644411 | Irradiation Enhances the Tumor Tropism and Therapeutic Potential of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Secreting Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells in Glioma Therapy |
| Q53950070 | Long-term tumor-free survival from treatment with the GFP-TRAIL fusion gene expressed from the hTERT promoter in breast cancer cells. |
| Q40705843 | Mechanisms involved in development of resistance to adenovirus-mediated proapoptotic gene therapy in DLD1 human colon cancer cell line. |
| Q37310677 | Mesenchymal stem cells expressing TRAIL lead to tumour growth inhibition in an experimental lung cancer model |
| Q35092291 | Modeling gene-environment interactions in malignant melanoma |
| Q37076207 | Molecular mechanisms of death ligand-mediated immune modulation: a gene therapy model to prolong islet survival in type 1 diabetes |
| Q33729242 | NF-κB targeting by way of IKK inhibition sensitizes lung cancer cells to adenovirus delivery of TRAIL |
| Q36041769 | Neural precursor cells and their role in neuro-oncology |
| Q42194180 | Neutrophil stimulation with Mycobacterium bovis bacillus Calmette-Guerin (BCG) results in the release of functional soluble TRAIL/Apo-2L |
| Q34234165 | No longer a molecular black box--new clues to apoptosis and drug resistance in melanoma |
| Q35371213 | Noninvasive imaging of therapeutic gene expression using a bidirectional transcriptional amplification strategy |
| Q40345895 | Oral adeno-associated virus-sTRAIL gene therapy suppresses human hepatocellular carcinoma growth in mice |
| Q34072314 | Overcoming hypoxic-resistance of tumor cells to TRAIL-induced apoptosis through melatonin |
| Q42278494 | Overexpression of Bcl2 abrogates chemo- and radiotherapy-induced sensitisation of NCI-H460 non-small-cell lung cancer cells to adenovirus-mediated expression of full-length TRAIL. |
| Q45864098 | PTEN and TRAIL genes loaded zein nanoparticles as potential therapy for hepatocellular carcinoma |
| Q54117497 | Pegylated liposomal‑paclitaxel induces ovarian cancer cell apoptosis via TNF‑induced ERK/AKT signaling pathway. |
| Q34134426 | Potent, tumor-specific gene expression in an orthotopic hepatoma rat model using a Survivin-targeted, amplifiable adenoviral vector |
| Q40643048 | Pretreatment of indole-3-carbinol augments TRAIL-induced apoptosis in a prostate cancer cell line, LNCaP. |
| Q40357610 | Prevention of posterior capsule opacification by the induction of therapeutic apoptosis of residual lens cells. |
| Q34313135 | Radiotherapy sensitization by tumor-specific TRAIL gene targeting improves survival of mice bearing human non-small cell lung cancer |
| Q44611172 | Real-time imaging of TRAIL-induced apoptosis of glioma tumors in vivo |
| Q45489118 | Recombinant adeno-associated virus-mediated TRAIL gene therapy suppresses liver metastatic tumors |
| Q40276197 | Recombinant adenoviruses expressing TRAIL demonstrate antitumor effects on non-small cell lung cancer (NSCLC). |
| Q40714107 | Regulation of Akt by EGF-R inhibitors, a possible mechanism of EGF-R inhibitor-enhanced TRAIL-induced apoptosis |
| Q40715403 | Regulation of TRAIL expression by the phosphatidylinositol 3-kinase/Akt/GSK-3 pathway in human colon cancer cells |
| Q43696432 | Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL. |
| Q34020374 | Role of caspase 8 as a determinant in trail sensitivity of neuroblastoma cell lines |
| Q40270141 | Sodium butyrate induced keratinocyte apoptosis. |
| Q40318203 | Specific resistance upon lentiviral TRAIL transfer by intracellular retention of TRAIL receptors |
| Q24810732 | Surface TRAIL decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells |
| Q37440765 | TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies |
| Q35756895 | TRAIL and viral infection |
| Q43963746 | TRAIL enhances thymidine kinase/ganciclovir gene therapy of neuroblastoma cells |
| Q37307340 | TRAIL gene therapy: from preclinical development to clinical application |
| Q35770748 | TRAIL protein expression in breast cancer cells correlates with nuclear grade |
| Q92833468 | TRAIL-based gene delivery and therapeutic strategies |
| Q57492228 | Targeted nonviral gene therapy in prostate cancer |
| Q35768756 | Targeting different types of human meningioma and glioma cells using a novel adenoviral vector expressing GFP-TRAIL fusion protein from hTERT promoter |
| Q40665736 | Targeting gene expression of the mouse uroplakin II promoter to human bladder cells |
| Q37356520 | Targeting multiple pathways in gliomas with stem cell and viral delivered S-TRAIL and Temozolomide |
| Q37882480 | Targeting the extrinsic apoptosis signaling pathway for cancer therapy |
| Q40262890 | The antitumor activity of TRAIL and IL-24 with replicating oncolytic adenovirus in colorectal cancer |
| Q38986804 | Therapeutic efficacy of intravenously administered transferrin-conjugated dendriplexes on prostate carcinomas |
| Q34193462 | Three-dimensional microscopy characterization of death receptor 5 expression by over-activated human primary CD4+ T cells and apoptosis |
| Q36836285 | Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Promotes Angiogenesis and Ischemia-Induced Neovascularization Via NADPH Oxidase 4 (NOX4) and Nitric Oxide-Dependent Mechanisms |
| Q37621564 | Tumor Necrosis Factor-related apoptosis-inducing ligand (TRAIL) Receptor-1 and Receptor-2 agonists for cancer therapy |
| Q44259102 | Tumor necrosis factor-related apoptosis inducing ligand-R4 decoy receptor expression is correlated with high Gleason scores, prostate-specific antigen recurrence, and decreased survival in patients with prostate carcinoma |
| Q44698226 | Tumor necrosis factor-related apoptosis-inducing ligand promotes migration of human bone marrow multipotent stromal cells. |
| Q35812718 | Tumor therapy mediated by lentiviral expression of shBcl-2 and S-TRAIL. |
Search more.